-
Uncategorized3 weeks ago
AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships
AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships
-
Uncategorized3 weeks agoASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.
-
Uncategorized3 weeks ago
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
-
Uncategorized3 weeks agoParkinson’s drug from Biogen, Denali comes up short
High level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain...
-
Uncategorized3 weeks ago
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout...
-
Uncategorized3 weeks agoSTAT+: EU and US advisers split over AstraZeneca breast cancer drug
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Merck’s bet on an antibody-drug...
-
Uncategorized3 weeks agoNews round-up from SLAS Europe
DDW reports on some key news releases that emerged out of this year’s SLAS Europe. Cenevo reinforces agentic AI approach with new AI-assistant Announced at SLAS Europe, lab management...
-
Uncategorized3 weeks ago
Why one health AI unicorn is giving away its service for free
Why one health AI unicorn is giving away its service for free
-
Uncategorized3 weeks ago
Recordati fields $12.4B go-private offer
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to...
-
Uncategorized3 weeks ago
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer
The agreement is the largest in a series of deals that Gilead Sciences has penned with Korea’s Yuhan.
Amgen shores up Tavneos’ FDA defense with Duke data analysis
